Skip to main content

Table 3 Comparison of patients that reported being much improved and those reporting less positive results after completing 3 years of Grazax treatment (n (%))

From: Sublingual grass allergen specific immunotherapy: a retrospective study of clinical outcome and discontinuation

Allergic symptoms had much improved during the latest grass pollen season compared to the season before you started using

 

Yes

(n = 55)

No

(n = 52)

p-value

Female

24 (45%)

29 (56%)

0.21

Age

42 ± 11

40 ± 11

0.39

Other allergies

35 (65%)

42 (81%)

0.06

Asthma

18 (33%)

29 (56%)

0.02

Year since treatment completion

3.5 ± 2.2

3.1 ± 2.3

0.36